Login to Your Account

Another DMD setback: PTC's Translarna stung by refuse to file letter from FDA

By Michael Fitzhugh
Staff Writer

Tuesday, February 23, 2016

The FDA's refusal to accept a new drug application for PTC Therapeutics Inc.'s DMD candidate Translarna (ataluren) left the company pondering next steps as its shares (NASDAQ:PTCT) plunged.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription